|
Synonyms: h-R3 | THERACIM® | Theraloc®
nimotuzumab is an approved drug (China, India, others (2014))
Compound class:
Antibody
Comment: Nimotuzumab is a monoclonal antibody directed agianst the epidermal growth factor receptor (EGFR), being developed as an antineoplastic agent.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis using the light chain variable region of nimotuzumab provides a 100% match with sequence 35 from patent US6506883 [1]. Biosimilar drug: Biocon Limited are developing BIOMAb-EGFRTM as a nimotuzumab biosimilar |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes. China (2014) | India (2014) | Others (2014) |
| International Nonproprietary Names |
|
| INN number | INN |
| 8545 | nimotuzumab |
| Synonyms |
| h-R3 | THERACIM® | Theraloc® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 76 |
| Other databases | |
| GtoPdb PubChem SID | 249565669 |
| Search PubMed clinical trials | nimotuzumab |
| Search PubMed titles | nimotuzumab |
| Search PubMed titles/abstracts | nimotuzumab |
| Wikipedia | Nimotuzumab |
